Back
Top 0.3%
11.8%
Top 61%
9.0%
Top 27%
7.8%
#1
7.8%
Top 16%
6.4%
Top 0.4%
6.4%
Top 0.4%
5.9%
Top 1%
5.9%
Top 8%
5.0%
Top 4%
3.6%
Top 14%
1.9%
Top 1%
1.9%
Top 13%
1.3%
Top 12%
0.9%
Top 3%
0.9%
Top 17%
0.9%
Top 0.9%
0.7%
Top 35%
0.7%
Top 10%
0.7%
Top 25%
0.5%
Population pharmacokinetics and target attainment of pretomanid in rifampicin-resistant Tuberculosis patients
2025-12-05
pharmacology and therapeutics
Title + abstract only
View on medRxiv
Show abstract
Pretomanid is a key component of the bedaquiline, pretomanid, linezolid with or without moxifloxacin (BPaL/M)regimen recommended for treatment of rifampicin-resistant tuberculosis (RR-TB). To support dose optimization and efficacy interpretation, we developed a pretomanid population pharmacokinetic (PK) model and evaluated exposure and probability of target attainment (PTA). Ninety-four RR-TB patients received daily oral pretomanid at 200 mg, and plasma samples were collected at multiple time po...
Predicted journal destinations
1
Clinical Pharmacology & Therapeutics
19 training papers
2
PLOS ONE
1737 training papers
3
Scientific Reports
701 training papers
4
Antimicrobial Agents and Chemotherapy
17 training papers
5
Nature Communications
483 training papers
6
British Journal of Clinical Pharmacology
21 training papers
7
Frontiers in Pharmacology
27 training papers
8
European Respiratory Journal
44 training papers
9
eLife
262 training papers
10
The Journal of Infectious Diseases
137 training papers
11
Clinical Infectious Diseases
219 training papers
12
American Journal of Respiratory and Critical Care Medicine
23 training papers
13
Frontiers in Medicine
99 training papers
14
PLOS Computational Biology
141 training papers
15
Communications Biology
36 training papers
16
PLOS Medicine
95 training papers
17
Journal of Antimicrobial Chemotherapy
19 training papers
18
BMC Medicine
155 training papers
19
Nature
58 training papers
20
Proceedings of the National Academy of Sciences
100 training papers